Stocks of Amarin Corp ADR (NASDAQ:AMRN) traded higher last session on Wall Street, up 7.07% to $1.06.
AMRN stock price is now -1.13% away from the 50-day moving average and 7.36% away from the 200-day moving average. The market capitalization of the company currently stands at $433.35M.
On October 25, 2023, Jefferies Downgraded its previous ‘Buy’ rating to ‘Hold’ on the stock reducing its target price from $3 to quote $1, while ‘JP Morgan’ rates the stock as ‘Underweight’
In other news, Holt Patrick, President and CEO bought 14,426 shares of the company’s stock on Jan 22 ’24. The stock was bought for $15,724 at an average price of $1.09. Upon completion of the transaction, the President and CEO now directly owns 314,426 shares in the company, valued at $0.33 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 12 ’23, Chief Scientific Officer Ketchum Steven B sold 34,131 shares of the business’s stock. A total of $26,963 was realized by selling the stock at an average price of $0.79. This leaves the insider owning 566,100 shares of the company worth $0.6 million. A total of 0.44% of the company’s stock is owned by insiders.
During the past 12 months, Amarin Corp ADR has had a low of $0.65 and a high of $1.50. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 2.80, and a quick ratio of 1.80. The fifty day moving average price for AMRN is $1.0704 and a two-hundred day moving average price translates $0.9869 for the stock.
The latest earnings results from Amarin Corp ADR (NASDAQ: AMRN) was released for Dec, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at -$0.01, beating analysts’ expectations of -$0.03 by 0.02. This compares to $0.00 EPS in the same period last year. The net profit margin was -19.23% and return on equity was -10.33% for AMRN. The company reported revenue of $74.71 million for the quarter, compared to $90.25 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -17.21 percent. For the current quarter, analysts expect AMRN to generate $57.3M in revenue.
